1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
New Journey Health Technology Group Co., Ltd.Class A

New Journey Health Technology Group Co., Ltd.Class A

SSZSE:002219
1.91
CNY
+0.02
(+1.06%)
0.01EPS
190.64P/E
5.97BMarket Cap
Oct 29Next Earn
New Journey Health Technology Group Co., Ltd.Class A
SZSE:002219
(Shenzhen Stock Exchange)

Recent

price

1.91

P/E

ratio

190.64

div

yld

1.14%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.2
0.2
0.22
0.37
0.44
0.68
1.15
1.82
2.06
1.97
1.5
1.62
0.97
1.16
1.16
0.93
0.85
Revenue per Share
0.04
0.05
0.05
0.11
0.17
0.19
0.21
0.11
-0.76
-1.35
-0.03
-0.2
0.05
0.01
0.03
0.01
0.01
Basic EPS, GAAP
0.02
0.06
0.05
0.01
0.11
-0.13
-0.52
-0.42
0.16
0.18
0.04
0.04
0.01
0.03
0.04
0.01
- -
Free Cash Flow per Basic Share
- -
0.01
0.01
0.01
0.04
0.03
0.01
0.11
0.17
0.21
0.04
0.03
0.08
0.03
0.04
0.03
0.02
Dividend per Share
0.28
0.32
0.36
0.52
0.66
1.97
2.19
2.25
1.45
0.1
0.07
0.83
0.53
0.62
0.59
0.58
0.57
Book Value per Share
0.27
0.31
0.28
0.26
0.32
1.37
1.52
0.1
-0.51
-0.59
-0.6
0.21
0.18
0.17
0.14
0.13
0.14
Tangible Book Value per Share
1,503
1,503
1,504
1,532
1,541
1,746
1,887
1,866
1,865
1,866
1,866
1,866
3,266
3,377
3,288
3,292
3,365
Basic Weighted Avg Shares
299
307
337
565
686
1,182
2,175
3,399
3,838
3,684
2,806
3,016
3,161
3,914
3,799
3,053
2,869
Sales/Revenue/Turnover
25.19
25.18
24.23
38.19
47.54
35.76
23.89
16.31
1.1
3.28
8.05
2.86
9.54
6.48
9.13
9.03
9.97
Operating Margin (%)
16
21
29
40
41
70
101
198
230
135
171
163
167
238
216
200
- -
Depreciation Expense
66
71
74
170
257
324
404
203
-1,418
-2,520
-52
-371
156
27
115
31
31
Net Income, GAAP
15.05
13.99
14.18
16.15
11.43
19.58
14.17
27.18
- -
- -
525.52
- -
12.1
- -
21.98
57.06
52.9
Effective Tax Rate (%)
22.04
23.22
21.86
30.07
37.53
27.39
18.56
5.97
-36.94
-68.38
-1.86
-12.32
4.94
0.69
3.02
1.01
1.06
Profit Margin (%)
230
312
268
189
107
1,355
1,237
-647
-668
-3,041
-2,889
-1,535
-1,527
-1,404
-1,531
-1,633
-1,582
Working Capital
- -
- -
3
2
1
33
10
504
1,589
300
291
335
457
823
593
472
425
LT Debt
414
477
561
821
1,055
3,803
4,173
4,348
2,858
208
158
1,586
1,766
2,171
2,039
2,012
2,036
Total Equity
14.2
12.36
9.67
18.72
19.43
9.49
8.22
3.48
- -
- -
-24.36
- -
5.11
- -
3.63
1.06
1.26
Return on Invested Capital (%)
16.43
15.23
12.33
20.84
22.22
13.14
9.52
5.23
- -
- -
-22.81
- -
7.39
- -
5.53
2.12
2.09
Return on Capital (%)
17.16
16.01
14.42
25.2
28.21
13.63
10.33
4.9
-41.1
-173.41
-31.79
-44.04
9.53
1.41
5.6
1.57
1.53
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,401
1,321
1,411
LT Borrowings
397
433
378
LT Finance Leases
75
51
47
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,387
3,452
3,452
Market Capitalization
7,215
8,630
5,972

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,908
1,849
1,942
Cash, Cash Equivalents & STI
396
252
368
Accounts Receivable, Net
1,218
1,281
1,207
Inventories
151
175
175
Total Current Liabilities
3,541
3,464
3,524
Payables & Accruals
- -
- -
- -
ST Debt
1,401
1,321
1,411
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
79.47%
186.35%
-1.32%
Free Cash Flow
16.42%
12.26%
-71.94%
Net Income, GAAP
-20.63%
127.6%
-73.04%
Sales/Revenue/Turnover
13.89%
2.71%
-19.64%
Total Cash Common Dividend
128.64%
61.73%
-14.83%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
953
957
861
1,118
3,799
2025
796
795
666
795
3,053
2026
720
688
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
- -
0.02
0.03
2025
0.01
- -
-0.01
0.02
0.01
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
0.01
0.03
2026
0.01
0.01
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
New Journey Health Technology Group Co., Ltd. (002219.SZ) operates as a healthcare company principally engaged in medical services and pharmaceutical manufacturing in China. The company provides medical services through a "1+N" innovative model featuring general hospitals and multiple specialist branches, including 3 tertiary hospitals and 14 secondary hospitals with nearly 10,000 beds across six regional medical centers in Liaoning, Henan, Jiangsu, Jiangxi, Sichuan, and Chongqing; these centers specialize in treating aging-related diseases such as tumors, cardiovascular and cerebrovascular conditions, orthopedics, neurology, neurosurgery, and bone disorders. In pharmaceuticals, it researches, develops, produces, and sells traditional Chinese medicines under the China-famous "Duyiwei" (Unique Flavor) brand, including Duyiwei capsules, Shenqi Schisandra tablets, Maiping tablets, Qianlieantong tablets, Gongzuoning capsules, ginseng and astragalus schisandra tablets, Jiuwei Qianghuo pills, Schisandra granules, and prostaglandin tablets; it also engages in Chinese herbal medicine cultivation, daily chemicals, health products, technology development, investment management, retail, and wholesale. Founded in 2001 and headquartered at 28/F, Fortune Financial Center, 5 East Third Ring Road, Beijing, China, the company, formerly known as Hengkang Medical Group Co., Ltd., is controlled by Xinmileage Health Group Co., Ltd. Recent developments include a subsidiary's plan announced in December 2024 to form a partnership for acquiring 100% equity in Chongqing New Journey Medical Management Co., Ltd. to strengthen medical services influence, optimize capital structure, and enhance competitiveness in existing business areas; additionally, it received CNY 685.8 million in funding from Beijing New Journey Health and reported Q2 2024 revenue growth of 16% to CNY 957.4 million.